Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Interferon recombinant

Insulin, interferon Recombinant E. coli Baker s yeast Human therapy... [Pg.2]

A study in 5 patients with stable ehronic active hepatitis B and 4 healthy subjects found that 20 hours after being given a single 9- or 18-million unit intramuscular injection of interferon (recombinant human interferon alfa A), the clearance of theophylline (given as intravenous aminophylline) was approximately halved (range 33 to 81%) in 8 of the 9 subjects. The mean theophylline elimination half-life was increased from 6.3 to 10.7 hours (1.5 to sixfold increases). In the healthy subjects the theophylline clearances were noted to have returned to their former values 4 weeks after the study. ... [Pg.1184]

Therapeutics. Therapeutic materials represent a class of polypeptides that are a low volume, high value product. The production system need not be very efficient but the quaHty of the recombinant protein has to be extremely pure (33,34). Thus high cost mammalian production systems can be tolerated. However, some of the therapeutic proteins such as insulin, human growth hormone, interleukins, interferon, and streptokinase are produced microbially. [Pg.249]

Several of these IFNs of mouse and human lymphocytes and fibroblasts are available commercially and have been best prepared in quantity by recombinant DNA procedures because they are produced in very small amounts by the cells. The commercial materials do not generally require further purification for their intended purposes. [Pestkas, Interferons and Interferon standards and general abbreviations. Methods Enzymol, Wiley Sons, 119 1986, ISBN 012182019X Lengyel, Biochemistry of interferons and their actions, Ann Bev Biochem 51 251-282 7982 De Maeyer and De Maeyer-Guignard, Interferons in The Cytokine Handbook, 3rd Edn, Thomson et al. Eds, pp. 491-516 7998 Academic Press, San Diego, ISBN 0126896623.]... [Pg.543]

Cellular cytokines (interferons, G-CSF) and immune response modifiers originally produced from human cells, most often leukocytes, have now been replaced with recombinant products with well-defined structure/function. Futuristic advances in experimental hematology portend development of human blood cells produced from the hemopoetic stem cells. Yet for the foreseeable future, homologous blood donated by healthy, altruistic voluntary blood donors remains the principal source of safe and adequate supply of blood and blood products for transfusion therapy. [Pg.265]

Morimoto, A., Murakami, M., Takada, M., Teshirogti, S., Watanabe, T. (1987). Fever and the acute phase response induced in rabbits by human recombinant interferon. J. Physiol. 391, 209-218. [Pg.457]

Abstract In 2007, the world celebrated the 50th anniversary of the discovery of interferon (IFN) by Isaacs and Lindemnann. Subsequently, the IFN-a gene was cloned, fully sequenced and IFN-a was produced in recombinant form. Recombinant IFN-a is now used as the basis for treatment of chronic hepatitis C virus infection and can also be used to treat certain forms of chronic hepatitis B virus infections. IFNs have also been used in other viral infections, although with less success. The antiviral mechanisms of IFNs are reviewed in this chapter as well as the utility of IFNs in the treatment of persistent viral infections. [Pg.204]

Bain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU, FisceUa M, Yu R, Osborn BE, Cronin PW, Ereimuth WW, McHutchison JG, Subramanian GM (2006) A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 44 671-678... [Pg.230]

Balan V Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH, Dickson RC, Post AB, Redfleld RR, Davis GL, Neumann AU, Osborn BE, Ereimuth WW, Subramanian GM (2006) A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy, Antivir Ther 11 35 5... [Pg.230]

Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, PeUiceUi A, Grisorio B, Barbarini G (1999) Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Scand J Gastroenterol 34 928-933... [Pg.230]

Carreno V, MarceUin P, Hadziyannis S, Salmeron J, Diago M, Kitis GE, Vafiadis I, Schalm SW, Zahm F, Manzarbeitia F, Jimenez FJ, Quiroga JA (1999) Retreatment of chrome hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. Hepatology 30 277-282... [Pg.231]

Gunsar E, Akarca US, Ersoz G, Kobak AC, Karasu Z, Yuce G, liter T, Batur Y (2005) Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther 10 721-726 Habersetzer E, Boyer N, MarceUin P, Badly F, Ahmed SN, Alam J, Benhamou JP, Trepo C (2000) A pdot study of recombinant interferon beta-la for the treatment of chronic hepatitis C. Liver 20 437 41... [Pg.234]

Hong SH, Cho O, Kim K, Shin HJ, Kotenko SV, Park S (2007) Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res 126 245-249 Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di BiscegUe A, Peters M, Waggoner JG, Park Y, Jones EA (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 315 1575-1578 Horiike N, Onji M (2003) Combination therapy with interferon-alpha and ribavirin as im-munomodulators in patients with chronic hepatitis C. J Gastroenterol 38 302-304... [Pg.234]

Kozlowski A, Charles SA, Harris JM (2001) Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 15 419 29 Krown SE, AeppU D, Balfour HH Jr (1999) Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 20 245-254 LaFleur DW, NardeUi B, Tsareva T, Mather D, Feng P, Semenuk M, Taylor K, Buergin M, Chinchilla D, Roshke V, Chen G, Ruben SM, Pitha PM, Coleman TA, Moore PA (2001) Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem 276 39765-39771... [Pg.236]

Osborn BL, Olsen HS, NardeUi B, Murray JH, Zhou JX, Garcia A, Moody G, Zaritskaya LS, Sung C (2002) Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 303 540-548 Ozes ON, Reiter Z, Klein S, Blatt LM, Taylor MW (1992) A comparison of interferon-Conl with natural recombinant interferons-alpha antiviral, antiproliferative, and natural kiUer-inducing activities. J Interferon Res 12 55-59... [Pg.238]

Peters M, Waiting DM, Kelly K, Davis GL, Waggoner JG, Hoofnagle JH (1986) Immunologic effects of interferon-alpha in man treatment with human recombinant interferon-alpha suppresses in vitro immunoglobulin production in patients with chronic type B hepatitis. J Immunol 137 3147-3152... [Pg.239]

Rosina E, Pintus C, Meschievitz C, Rizzedo M (1991) A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis a multicenter Italian study. Hepatology 13 1052-1056... [Pg.239]

Disappoinhngly low yields of F-IFN and Le-IFN are achieved fiorn eukaryotie eells. Recently, however, recombinant DNA technology has been employed to produee interferon in prokaiyotic cells (bacteria). This aspeet is considered in more detail in Chapter 24. [Pg.128]

BollonA.P. (l9S4)Recombinant DNA Products Insulin, Interferon andGrowth Hormone. Boca Raton, Florida CRC Press. [Pg.468]

Biotechnology era beginning First recombinant DNA products Human insulin Human growth hormone Interferons, etc. Monoclonal antibodies Nucleotide blockage Growth in use of natural products and neutraceuticals... [Pg.23]

J. L. Cleland and A. J. Jones, Stable formulations of recombinant human growth hormone and interferon-y for microencapsulation in biodegradable microspheres, Phar. Res, 13(10), 1464 (1996). [Pg.721]

Davis, G. L., et al. (1989). Treatment of chronic hepatitis C with recombinant interferon alpha. A multi-center randomized, controlled trial. N. Engl. J. Med 321,1501-1506. [Pg.232]

See other pages where Interferon recombinant is mentioned: [Pg.60]    [Pg.101]    [Pg.60]    [Pg.101]    [Pg.241]    [Pg.206]    [Pg.238]    [Pg.40]    [Pg.41]    [Pg.235]    [Pg.406]    [Pg.445]    [Pg.544]    [Pg.265]    [Pg.410]    [Pg.411]    [Pg.639]    [Pg.453]    [Pg.232]    [Pg.232]    [Pg.234]    [Pg.238]    [Pg.266]    [Pg.305]    [Pg.407]    [Pg.461]    [Pg.311]    [Pg.38]    [Pg.331]   
See also in sourсe #XX -- [ Pg.285 ]

See also in sourсe #XX -- [ Pg.138 ]



SEARCH



Interferon alfa-2B, recombinant

Recombinant human interferons

Recombination interferons role

© 2024 chempedia.info